High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Stupp
R
R
Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland.
Tonn
J-C
JC
Brada
M
M
Pentheroudakis
G
G
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005060:Europe / Q000453:epidemiology; D005500:Follow-Up Studies; D005819:Genetic Markers; D005910:Glioma / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D006801:Humans; D015994:Incidence; D019656:Loss of Heterozygosity; D009367:Neoplasm Staging; D011379:Prognosis; D011878:Radiotherapy; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D055502:Secondary Prevention; D000077204:Temozolomide; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D018906:Antineoplastic Agents, Alkylating; D005819:Genetic Markers; D003606:Dacarbazine; D000077204:Temozolomide